VJHemOnc is committed to improving our service to you

MPN Advances Day 2019 | Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways

VJHemOnc is committed to improving our service to you

Ruben Mesa

Speaking at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the latest treatments in development for myelofibrosis, as well as understanding of the disease. He highlights JAK inhibitors, as well as other pathway inhibitors such as LSD1, BET, MDM2 and TGF-β.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter